001     179337
005     20240229145540.0
024 7 _ |a 10.1093/ije/dyac042
|2 doi
024 7 _ |a pmid:35312764
|2 pmid
024 7 _ |a 0300-5771
|2 ISSN
024 7 _ |a 1464-3685
|2 ISSN
024 7 _ |a altmetric:125086488
|2 altmetric
037 _ _ |a DKFZ-2022-00603
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Alcala, Karine
|b 0
245 _ _ |a The relationship between blood pressure and risk of renal cell carcinoma.
260 _ _ |a Oxford
|c 2022
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660553539_9237
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Aug 10;51(4):1317-1327
520 _ _ |a The relation between blood pressure and kidney cancer risk is well established but complex and different study designs have reported discrepant findings on the relative importance of diastolic blood pressure (DBP) and systolic blood pressure (SBP). In this study, we sought to describe the temporal relation between diastolic and SBP with renal cell carcinoma (RCC) risk in detail.Our study involved two prospective cohorts: the European Prospective Investigation into Cancer and Nutrition study and UK Biobank, including >700 000 participants and 1692 incident RCC cases. Risk analyses were conducted using flexible parametric survival models for DBP and SBP both separately as well as with mutuality adjustment and then adjustment for extended risk factors. We also carried out univariable and multivariable Mendelian randomization (MR) analyses (DBP: ninstruments = 251, SBP: ninstruments = 213) to complement the analyses of measured DBP and SBP.In the univariable analysis, we observed clear positive associations with RCC risk for both diastolic and SBP when measured ≥5 years before diagnosis and suggestive evidence for a stronger risk association in the year leading up to diagnosis. In mutually adjusted analysis, the long-term risk association of DBP remained, with a hazard ratio (HR) per standard deviation increment 10 years before diagnosis (HR10y) of 1.20 (95% CI: 1.10-1.30), whereas the association of SBP was attenuated (HR10y: 1.00, 95% CI: 0.91-1.10). In the complementary multivariable MR analysis, we observed an odds ratio for a 1-SD increment (ORsd) of 1.34 (95% CI: 1.08-1.67) for genetically predicted DBP and 0.70 (95% CI: 0.56-0.88) for genetically predicted SBP.The results of this observational and MR study are consistent with an important role of DBP in RCC aetiology. The relation between SBP and RCC risk was less clear but does not appear to be independent of DBP.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Mendelian randomization
|2 Other
650 _ 7 |a RCC
|2 Other
650 _ 7 |a diastolic blood pressure
|2 Other
650 _ 7 |a kidney cancer
|2 Other
650 _ 7 |a systolic blood pressure
|2 Other
700 1 _ |a Mariosa, Daniela
|b 1
700 1 _ |a Smith-Byrne, Karl
|b 2
700 1 _ |a Nasrollahzadeh Nesheli, Dariush
|b 3
700 1 _ |a Carreras-Torres, Robert
|b 4
700 1 _ |a Ardanaz Aicua, Eva
|b 5
700 1 _ |a Bondonno, Nicola P
|b 6
700 1 _ |a Bonet, Catalina
|b 7
700 1 _ |a Brunström, Mattias
|0 0000-0002-7054-0905
|b 8
700 1 _ |a Bueno-de-Mesquita, Bas
|b 9
700 1 _ |a Chirlaque, María-Dolores
|b 10
700 1 _ |a Christakoudi, Sofia
|0 0000-0001-9219-4436
|b 11
700 1 _ |a Heath, Alicia K
|0 0000-0001-6517-1300
|b 12
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 13
|u dkfz
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 14
|u dkfz
700 1 _ |a Krogh, Vittorio
|0 0000-0003-0122-8624
|b 15
700 1 _ |a Ljungberg, Börje
|b 16
700 1 _ |a Martin, Richard M
|b 17
700 1 _ |a May, Anne
|b 18
700 1 _ |a Melander, Olle
|b 19
700 1 _ |a Palli, Domenico
|b 20
700 1 _ |a Rodriguez-Barranco, Miguel
|b 21
700 1 _ |a Sacerdote, Carlotta
|0 0000-0002-8008-5096
|b 22
700 1 _ |a Stocks, Tanja
|0 0000-0002-0904-0557
|b 23
700 1 _ |a Tjønneland, Anne
|0 0000-0003-4385-2097
|b 24
700 1 _ |a Travis, Ruth C
|b 25
700 1 _ |a Vermeulen, Roel
|0 0000-0003-4082-8163
|b 26
700 1 _ |a Chanock, Stephen
|0 0000-0002-2324-3393
|b 27
700 1 _ |a Purdue, Mark
|b 28
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 29
700 1 _ |a Muller, David
|b 30
700 1 _ |a Brennan, Paul
|b 31
700 1 _ |a Johansson, Mattias
|0 0000-0002-3116-5081
|b 32
773 _ _ |a 10.1093/ije/dyac042
|0 PERI:(DE-600)1494592-7
|n 4
|p 1317-1327
|t International journal of epidemiology
|v 51
|y 2022
|x 0300-5771
909 C O |p VDB
|o oai:inrepo02.dkfz.de:179337
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-08
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-08
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J EPIDEMIOL : 2021
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-08
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-08
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J EPIDEMIOL : 2021
|d 2022-11-08
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21